Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

VERRICA PHARMACEUTICALS INC.

(VRCA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Verrica Pharma Shares Slide 25% After Company Receives Letter From FDA

09/20/2021 | 05:49pm EDT

By Stephen Nakrosis

Shares of Verrica Pharmaceuticals Inc. are lower in Monday's late-trading session, after the company said it received a complete response letter from the U.S. Food and Drug Administration identifying deficiencies at a contract manufacturer's facility for its VP-102.

The company said it filed a new drug application for VP-102 to treat molloscum contagiosum, a viral infection affecting the skin.

Verrica said the deficiencies identified by the FDA "are not specifically related to the manufacturing of VP-102 but instead raise general quality issues at the facility." The company added, "the FDA did not identify any clinical, safety or product specific chemistry, manufacturing, and controls deficiencies related to VP-102."

The contract manufacturing organization advised Verrica it is "expecting a satisfactory resolution of the facility's identified deficiencies from the FDA within the next 30 business days," Verrica said.

At 5:23 p.m. ET, shares of Verrica were trading 24.77% lower at $9.05 a share. Volume at the time topped 164,000 shares.

The company's stock finished the day's regular-trading session with a 1.15% loss, closing at $12.03 per share.

Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

(END) Dow Jones Newswires

09-20-21 1748ET

All news about VERRICA PHARMACEUTICALS INC.
09/29VERRICA PHARMACEUTICALS : Company Presentation
PU
09/29VERRICA PHARMACEUTICALS INC. : Regulation FD Disclosure, Financial Statements and Exhibits..
AQ
09/23SHAREHOLDER ALERT : Pomerantz Law Firm Investigates Claims On Behalf of Investors Verrica ..
PR
09/22VERRICA PHARMACEUTICALS : HC Wainwright Cuts Price Target on Verrica Pharmaceuticals to $2..
MT
09/21VERRICA PHARMACEUTICALS : Northland Securities Adjusts Verrica Pharmaceuticals PT to $18 F..
MT
09/21Verrica Pharmaceuticals Shares Drop 17% After FDA Complete Response Letter
DJ
09/21Wall Street Set for Higher Open, Fed Meeting in Focus
MT
09/21VERRICA PHARMACEUTICALS : Needham Cuts Price Target on Verrica Pharmaceuticals to $20 from..
MT
09/21VERRICA PHARMACEUTICALS : RBC Cuts Price Target on Verrica Pharmaceuticals to $16 From $19..
MT
09/21VERRICA PHARMACEUTICALS : FDA Turns Down Verrica's New Drug Application for Skin Infection..
MT
More news
Analyst Recommendations on VERRICA PHARMACEUTICALS INC.
More recommendations
Financials (USD)
Sales 2021 9,80 M - -
Net income 2021 -44,9 M - -
Net Debt 2021 - - -
P/E ratio 2021 -7,97x
Yield 2021 -
Capitalization 347 M 347 M -
Capi. / Sales 2021 35,4x
Capi. / Sales 2022 10,1x
Nbr of Employees 29
Free-Float 35,9%
Chart VERRICA PHARMACEUTICALS INC.
Duration : Period :
Verrica Pharmaceuticals Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VERRICA PHARMACEUTICALS INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 12,60 $
Average target price 19,83 $
Spread / Average Target 57,4%
EPS Revisions
Managers and Directors
Ted White President, Chief Executive Officer & Director
Terry Kohler Chief Financial & Accounting Officer
Paul B. Manning Chairman
Gary Goldenberg Chief Medical Officer
Eugene Scavola Executive Vice President-Technical Operations
Sector and Competitors
1st jan.Capi. (M$)
VERRICA PHARMACEUTICALS INC.9.47%347
JOHNSON & JOHNSON3.83%430 148
ROCHE HOLDING AG15.79%339 425
PFIZER, INC.16.27%240 303
NOVO NORDISK A/S56.55%239 079
ELI LILLY AND COMPANY42.84%218 640